Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
复制标题
DOI：
10.1093/annonc/mdm501
复制
发表时间：
2008-02-01
影响因子：
50.5
通讯作者：
Mencoboni, M.
中科院分区：
文献类型：
--
作者：
Castagneto, B.;Botta, M.;Mencoboni, M.
背景资料：本研究的目的是评价培美曲塞和卡铂联合作为恶性胸膜间皮瘤（MPM）一线化疗的活性和毒性。患者和方法：入选了可测量的晚期MPM和东部肿瘤协作组（ECOG）体能状态（PS）为0至2的患者。方案为培美曲塞500 mg/m2联合卡铂曲线下面积5，每21天给药一次。共有76名患者接受了治疗。中位年龄为65岁，中位ECOG PS为zero.Results：3级血液学毒性，根据世界卫生组织的标准，36例（47.3%）患者，4级血液学毒性5例（6.5%）。有16例（21%）部分缓解和3例（4%）完全缓解，总缓解率为19例（25%）[95%置信区间（CI）15.3-34.7]。共有29例（39%）（95% CI 28-48）患者报告疾病稳定。中位生存期估计为14个月。结论：卡铂和培美曲塞的联合用药具有中等活性，毒性可以接受。
Background: The aim of this study was to evaluate the activity and toxicity of pemetrexed and carboplatin combination as first-line chemotherapy in malignant pleural mesothelioma (MPM).Patients and methods: Patients with measurable advanced MPM and a zero to two Eastern Cooperative Oncology Group (ECOG) performance status (PS) were enrolled. The schedule was pemetrexed 500 mg/m(2) in combination with carboplatin area under the curve 5, every 21 days. In all, 76 patients were treated. Median age was 65 years; median ECOG PS was zero.Results: Grade 3 hematological toxicity according to World Health Organization criteria was seen in 36 (47.3%) patients; grade 4 hematological toxicity in 5 (6.5%) patients. There were 16 (21%) partial responses and 3 (4%) complete responses, for an overall response rate of 19 (25%) [95% confidence interval (CI) 15.3-34.7]. In all, 29 (39%) (95% CI 28-48) patients reported stable disease. The median survival was estimated at 14 months.Conclusion: This combination of carboplatin and pemetrexed is moderately active and the toxicity is acceptable.